The Apollo Therapeutics Fund offers Imperial academics and partners a new opportunity to drive forward therapeutic innovation.
The collaboration between companies and technology transfer offices has established a fund of £40 million – supporting the translation of outstanding academic science into innovative new medicines for a wide range of diseases, from cancer to infectious diseases. The consortium behind the Fund consists of AstraZeneca, GlaxoSmithKline, Johnson & Johnson and Imperial Innovations, Cambridge Enterprise and UCL Business – the technology transfer offices responsible for commercialising the research from Imperial College London, UCL and the University of Cambridge respectively. The Fund is open to applications from academics based in the three universities behind the participating technology transfer offices.
Read more on Imperial News